Cara Therapeutics - CARA Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $11.12
  • Forecasted Upside: 1,556.73%
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$0.67
▼ -0.06 (-8.21%)

This chart shows the closing price for CARA by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Cara Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CARA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CARA

Analyst Price Target is $11.12
▲ +1,556.73% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Cara Therapeutics in the last 3 months. The average price target is $11.12, with a high forecast of $25.00 and a low forecast of $3.60. The average price target represents a 1,556.73% upside from the last price of $0.67.

This chart shows the closing price for CARA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 4 contributing investment analysts is to moderate buy stock in Cara Therapeutics. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
12/2/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
3/2/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
5/31/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
8/29/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
11/27/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
2/25/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/25/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
5/25/2024

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/23/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$5.00Low
5/15/2024HC WainwrightReiterated RatingBuy ➝ Buy$3.60Low
5/14/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$5.00Low
4/10/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$5.00Low
3/28/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$5.00Low
3/6/2024Canaccord Genuity GroupLower TargetBuy ➝ Buy$11.00 ➝ $10.00Low
3/5/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$5.00Low
1/22/2024Needham & Company LLCLower TargetBuy ➝ Buy$6.00 ➝ $5.00Low
12/19/2023HC WainwrightLower TargetBuy ➝ Buy$7.00 ➝ $2.50Low
12/18/2023Needham & Company LLCLower TargetBuy ➝ Buy$22.00 ➝ $6.00Low
11/14/2023Piper SandlerReiterated RatingOverweight ➝ NeutralLow
10/19/2023HC WainwrightLower TargetBuy ➝ Buy$15.00 ➝ $7.00Low
8/8/2023Piper SandlerLower TargetOverweight ➝ Overweight$13.00 ➝ $12.00Low
8/8/2023Stifel NicolausLower Target$28.00 ➝ $25.00Low
8/8/2023Needham & Company LLCReiterated RatingBuy ➝ Buy$22.00Low
5/16/2023Bank of AmericaLower Target$6.00 ➝ $4.00Low
5/16/2023HC WainwrightLower Target$20.00 ➝ $15.00Low
4/4/2023Needham & Company LLCReiterated RatingBuy$22.00Low
3/7/2023Canaccord Genuity GroupLower TargetBuy$29.00 ➝ $25.00Low
3/7/2023JPMorgan Chase & Co.Lower TargetOverweight$19.00 ➝ $16.00Low
3/7/2023Bank of AmericaDowngradeNeutral ➝ Underperform$13.00 ➝ $6.00Low
3/7/2023Needham & Company LLCLower TargetBuy$26.00 ➝ $22.00Low
3/7/2023HC WainwrightLower TargetBuy$25.00 ➝ $20.00Low
3/7/2023Piper SandlerLower TargetOverweight$25.00 ➝ $13.00Low
2/17/2023Needham & Company LLCReiterated RatingBuy$26.00N/A
2/14/2023HC WainwrightLower TargetBuy$30.00 ➝ $25.00Low
11/15/2022Piper SandlerLower Target$25.00N/A
3/14/2022Canaccord Genuity GroupLower Target$33.00 ➝ $29.00High
3/14/2022HC WainwrightLower TargetBuy$35.00 ➝ $30.00Low
3/8/2022JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight$17.00 ➝ $20.00High
8/24/2021Needham & Company LLCInitiated CoverageBuy$26.00High
8/24/2021HC WainwrightBoost TargetBuy$33.00 ➝ $35.00High
8/10/2021Needham & Company LLCInitiated CoverageBuy$26.00High
8/3/2021JPMorgan Chase & Co.Initiated CoverageNeutral$16.00High
4/29/2021Needham & Company LLCLower TargetBuy$35.00 ➝ $26.00High
4/15/2021Needham & Company LLCReiterated RatingBuy$35.00Low
8/11/2020Needham & Company LLCReiterated RatingBuy$35.00Low
6/18/2020Needham & Company LLCReiterated RatingBuy$35.00Medium
5/19/2020Cantor FitzgeraldBoost TargetOverweight$34.00 ➝ $40.00Low
4/22/2020Cantor FitzgeraldBoost TargetOverweight$26.00 ➝ $34.00Medium
4/21/2020Needham & Company LLCInitiated CoverageBuy$35.00Low
4/21/2020HC WainwrightBoost TargetPositive ➝ Buy$30.00 ➝ $33.00High
12/4/2019Cantor FitzgeraldBoost Target$29.00 ➝ $33.00High
12/3/2019Needham & Company LLCReiterated RatingBuy$35.00High
12/3/2019HC WainwrightReiterated RatingBuy$30.00High
10/17/2019Needham & Company LLCReiterated RatingBuy$35.00Low
8/12/2019HC WainwrightReiterated RatingBuy ➝ Buy$31.00 ➝ $30.00Low
7/30/2019Piper Sandler CompaniesBoost TargetOverweight$35.00 ➝ $39.00Medium
7/22/2019HC WainwrightBoost TargetBuy ➝ Average$28.00 ➝ $31.00Low
5/29/2019LaidlawBoost TargetBuy$26.00 ➝ $32.00Low
5/29/2019HC WainwrightBoost TargetBuy$26.00 ➝ $28.00High
5/29/2019Needham & Company LLCBoost TargetBuy$28.00 ➝ $35.00High
(Data available from 5/25/2019 forward)

News Sentiment Rating

-0.07 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/28/2023
  • 4 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
11/27/2023
  • 1 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
12/27/2023
  • 0 very positive mentions
  • 4 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
1/26/2024
  • 1 very positive mentions
  • 11 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
2/25/2024
  • 3 very positive mentions
  • 15 positive mentions
  • 4 negative mentions
  • 6 very negative mentions
3/26/2024
  • 3 very positive mentions
  • 13 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/25/2024
  • 0 very positive mentions
  • 13 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
5/25/2024

Current Sentiment

  • 0 very positive mentions
  • 13 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Cara Therapeutics logo
Cara Therapeutics, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. It also develops Oral difelikefalin, which is in Phase II/III clinical trial to treat chronic pruritus with notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; Vifor Fresenius Medical Care Renal Pharma Ltd. development and commercialization of KORSUVA injection for the treatment of moderate-to-severe pruritus in adult patients undergoing hemodialysis; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.
Read More

Today's Range

Now: $0.67
Low: $0.67
High: $0.76

50 Day Range

MA: $0.79
Low: $0.66
High: $0.92

52 Week Range

Now: $0.67
Low: $0.50
High: $4.45

Volume

346,607 shs

Average Volume

283,710 shs

Market Capitalization

$36.70 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.74

Frequently Asked Questions

What sell-side analysts currently cover shares of Cara Therapeutics?

The following Wall Street research analysts have issued stock ratings on Cara Therapeutics in the last year: Canaccord Genuity Group Inc., HC Wainwright, Needham & Company LLC, Piper Sandler, Stifel Nicolaus, and StockNews.com.
View the latest analyst ratings for CARA.

What is the current price target for Cara Therapeutics?

5 Wall Street analysts have set twelve-month price targets for Cara Therapeutics in the last year. Their average twelve-month price target is $11.12, suggesting a possible upside of 1,556.7%. Stifel Nicolaus has the highest price target set, predicting CARA will reach $25.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $3.60 for Cara Therapeutics in the next year.
View the latest price targets for CARA.

What is the current consensus analyst rating for Cara Therapeutics?

Cara Therapeutics currently has 1 hold rating and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for CARA.

What other companies compete with Cara Therapeutics?

Other companies that are similar to Cara Therapeutics include Sagimet Biosciences, Cybin, RAPT Therapeutics, InterCure and Rezolute. Learn More about companies similar to Cara Therapeutics.

How do I contact Cara Therapeutics' investor relations team?

Cara Therapeutics' physical mailing address is 107 ELM STREET 9TH FLOOR, STAMFORD CT, 06902. The biopharmaceutical company's listed phone number is (203) 406-3700 and its investor relations email address is [email protected]. The official website for Cara Therapeutics is www.caratherapeutics.com. Learn More about contacing Cara Therapeutics investor relations.